Targeted Therapy | Novartis

Story
Apr 08, 2024

Drug delivery, service delivery, and the future of cancer care
Press Release
Jun 01, 2023

Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
Story
Jun 13, 2022

Prostate Cancer: A collective commitment to serving underserved communities
Press Release
Nov 08, 2021

Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021
Press Release
Sep 30, 2021

Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
Press Release
Sep 29, 2021

New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis
Press Release
Sep 29, 2021

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients
Press Release
Jan 06, 2020

Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
Press Release
Jan 06, 2020

Novartis completes tender offer for all outstanding shares of The Medicines Company
Press Release
Dec 09, 2019

Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Story
Nov 08, 2019

Turning the power of nuclear technology into a medical force
Story
May 29, 2018

Immuno-oncology researchers seek to build smart drug combos